Emergent BioSolutions Inc EBS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2006-11-15 |
| Shares Out. | 51,600,000 |
| Website | emergentbiosolutions.com/ ↗ |
| Phone | 12406313200 |
| Employees | 900 |
| Revenue | $156.1M |
| Gross Profit | $84.1M |
| Net Income | $6.8M |
| Free Cash Flow | $135.4M |
| Total Assets | $1.32B |
| Total Liabilities | $797.3M |
| Equity | $523.1M |
About Emergent BioSolutions Inc
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Emergent BioSolutions Inc is a publicly traded company under the ticker symbol EBS on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)